Jennifer Richer
Concepts (448)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 16 | 2025 | 202 | 6.580 |
Why?
| | Receptors, Androgen | 13 | 2023 | 150 | 5.040 |
Why?
| | Breast Neoplasms | 45 | 2025 | 2234 | 3.880 |
Why?
| | MicroRNAs | 17 | 2018 | 692 | 3.670 |
Why?
| | Androgen Receptor Antagonists | 8 | 2021 | 34 | 2.410 |
Why?
| | Anoikis | 7 | 2021 | 31 | 2.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 35 | 2025 | 1396 | 2.160 |
Why?
| | Tryptophan | 4 | 2024 | 183 | 1.920 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3406 | 1.840 |
Why?
| | Receptors, Progesterone | 24 | 2016 | 349 | 1.830 |
Why?
| | Estrogen Receptor alpha | 6 | 2022 | 145 | 1.830 |
Why?
| | Phenylthiohydantoin | 6 | 2017 | 42 | 1.710 |
Why?
| | Tryptophan Oxygenase | 5 | 2024 | 34 | 1.660 |
Why?
| | Receptors, Estrogen | 14 | 2020 | 436 | 1.350 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 562 | 1.150 |
Why?
| | Progesterone | 16 | 2014 | 254 | 0.980 |
Why?
| | Neoplasm Invasiveness | 4 | 2024 | 507 | 0.980 |
Why?
| | Progestins | 6 | 2014 | 78 | 0.950 |
Why?
| | Tamoxifen | 10 | 2016 | 202 | 0.940 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 56 | 0.890 |
Why?
| | Ribonuclease III | 2 | 2016 | 40 | 0.840 |
Why?
| | Neoplastic Stem Cells | 3 | 2017 | 399 | 0.810 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 76 | 0.810 |
Why?
| | Epithelial Cells | 3 | 2022 | 1094 | 0.810 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2018 | 209 | 0.790 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2020 | 800 | 0.780 |
Why?
| | Adipokines | 2 | 2024 | 49 | 0.780 |
Why?
| | Receptor, ErbB-2 | 4 | 2017 | 340 | 0.780 |
Why?
| | Biomarkers, Tumor | 7 | 2021 | 1272 | 0.770 |
Why?
| | Cell Proliferation | 14 | 2021 | 2476 | 0.760 |
Why?
| | Kallikreins | 1 | 2021 | 29 | 0.740 |
Why?
| | Gene Expression Profiling | 11 | 2018 | 1772 | 0.710 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 161 | 0.700 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1058 | 0.680 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 162 | 0.670 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 181 | 0.670 |
Why?
| | Endometrial Neoplasms | 6 | 2011 | 199 | 0.660 |
Why?
| | Trophoblasts | 1 | 2022 | 199 | 0.660 |
Why?
| | Immunohistochemistry | 8 | 2017 | 1733 | 0.660 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 165 | 0.650 |
Why?
| | Cell Movement | 9 | 2020 | 968 | 0.650 |
Why?
| | Androgen Antagonists | 3 | 2017 | 82 | 0.650 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 405 | 0.640 |
Why?
| | Transcription Factors | 13 | 2023 | 1718 | 0.640 |
Why?
| | Mammary Glands, Animal | 4 | 2022 | 129 | 0.630 |
Why?
| | Female | 64 | 2025 | 72816 | 0.630 |
Why?
| | Alternative Splicing | 2 | 2018 | 229 | 0.620 |
Why?
| | Homeodomain Proteins | 5 | 2014 | 506 | 0.620 |
Why?
| | Repressor Proteins | 6 | 2018 | 427 | 0.610 |
Why?
| | Cell Cycle | 4 | 2021 | 601 | 0.600 |
Why?
| | Humans | 92 | 2025 | 136803 | 0.590 |
Why?
| | Up-Regulation | 7 | 2020 | 844 | 0.590 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 53 | 0.580 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2017 | 68 | 0.570 |
Why?
| | Animals | 39 | 2025 | 36850 | 0.540 |
Why?
| | Mice | 24 | 2025 | 17759 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 868 | 0.530 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 50 | 0.530 |
Why?
| | Nitriles | 6 | 2017 | 172 | 0.520 |
Why?
| | Benzamides | 6 | 2017 | 216 | 0.520 |
Why?
| | Lactation | 2 | 2022 | 181 | 0.520 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 140 | 0.510 |
Why?
| | Lipogenesis | 1 | 2016 | 61 | 0.510 |
Why?
| | Paclitaxel | 3 | 2017 | 227 | 0.500 |
Why?
| | Antibody Specificity | 1 | 2016 | 189 | 0.500 |
Why?
| | Antineoplastic Agents | 6 | 2018 | 2123 | 0.480 |
Why?
| | Receptor, trkB | 2 | 2012 | 33 | 0.480 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2015 | 56 | 0.470 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.450 |
Why?
| | Apoptosis | 11 | 2020 | 2552 | 0.450 |
Why?
| | Kynurenine | 4 | 2024 | 114 | 0.440 |
Why?
| | RNA Interference | 3 | 2015 | 466 | 0.440 |
Why?
| | Antibodies | 1 | 2016 | 411 | 0.440 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 412 | 0.430 |
Why?
| | Receptors, Steroid | 2 | 2010 | 50 | 0.420 |
Why?
| | Metformin | 2 | 2014 | 330 | 0.420 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 672 | 0.410 |
Why?
| | Gene Expression Regulation | 8 | 2016 | 2605 | 0.400 |
Why?
| | Signal Transduction | 18 | 2025 | 5077 | 0.390 |
Why?
| | Chromatin | 1 | 2016 | 519 | 0.390 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 913 | 0.380 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 403 | 0.380 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 66 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1684 | 0.370 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 49 | 0.370 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 75 | 0.370 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 161 | 0.360 |
Why?
| | Disease Progression | 6 | 2018 | 2751 | 0.360 |
Why?
| | Endometrium | 2 | 2008 | 58 | 0.350 |
Why?
| | NF-kappa B | 3 | 2025 | 691 | 0.340 |
Why?
| | Transcriptional Activation | 5 | 2017 | 378 | 0.340 |
Why?
| | Mice, SCID | 4 | 2020 | 366 | 0.340 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 327 | 0.320 |
Why?
| | Tubulin Modulators | 1 | 2009 | 9 | 0.320 |
Why?
| | Cells | 1 | 2009 | 25 | 0.310 |
Why?
| | Estradiol | 6 | 2016 | 518 | 0.310 |
Why?
| | 3' Untranslated Regions | 4 | 2014 | 145 | 0.310 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 24 | 0.310 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 443 | 0.300 |
Why?
| | Cadherins | 4 | 2012 | 205 | 0.300 |
Why?
| | Uterine Neoplasms | 2 | 2008 | 109 | 0.300 |
Why?
| | Neoplasms | 5 | 2022 | 2643 | 0.290 |
Why?
| | Dirofilaria immitis | 3 | 2010 | 3 | 0.290 |
Why?
| | Mice, Nude | 5 | 2017 | 696 | 0.280 |
Why?
| | Feedback, Physiological | 2 | 2021 | 77 | 0.270 |
Why?
| | Trastuzumab | 2 | 2017 | 95 | 0.270 |
Why?
| | Mutation | 7 | 2022 | 3947 | 0.260 |
Why?
| | Cell Nucleus | 5 | 2017 | 617 | 0.260 |
Why?
| | Transfection | 5 | 2012 | 941 | 0.260 |
Why?
| | MCF-7 Cells | 3 | 2016 | 124 | 0.260 |
Why?
| | Microtubules | 1 | 2009 | 270 | 0.260 |
Why?
| | Epidermal Growth Factor | 4 | 2005 | 175 | 0.250 |
Why?
| | Genetic Diseases, Inborn | 2 | 2017 | 42 | 0.250 |
Why?
| | Fibrillin-1 | 1 | 2024 | 6 | 0.230 |
Why?
| | Anilides | 2 | 2016 | 73 | 0.230 |
Why?
| | Mice, Inbred NOD | 3 | 2020 | 600 | 0.230 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 115 | 0.230 |
Why?
| | Marfan Syndrome | 1 | 2024 | 41 | 0.230 |
Why?
| | Down-Regulation | 6 | 2016 | 656 | 0.220 |
Why?
| | Cell Differentiation | 1 | 2012 | 1982 | 0.220 |
Why?
| | Microarray Analysis | 2 | 2016 | 116 | 0.220 |
Why?
| | Gene Expression | 4 | 2020 | 1500 | 0.220 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2489 | 0.210 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.210 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 411 | 0.210 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 766 | 0.210 |
Why?
| | Tumor Cells, Cultured | 11 | 2020 | 953 | 0.190 |
Why?
| | Milk Proteins | 2 | 1999 | 34 | 0.190 |
Why?
| | Mammary Glands, Human | 2 | 2014 | 64 | 0.190 |
Why?
| | Genetic Variation | 2 | 2024 | 985 | 0.190 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 93 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 657 | 0.180 |
Why?
| | Epithelium | 1 | 2022 | 311 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2022 | 80 | 0.180 |
Why?
| | Estrogens | 3 | 2020 | 368 | 0.180 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2163 | 0.180 |
Why?
| | Promoter Regions, Genetic | 6 | 2014 | 1249 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 116 | 0.170 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 434 | 0.170 |
Why?
| | Semaphorins | 1 | 2020 | 32 | 0.170 |
Why?
| | DNA-Binding Proteins | 6 | 2018 | 1501 | 0.170 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 63 | 0.170 |
Why?
| | Epoxy Compounds | 1 | 2020 | 33 | 0.170 |
Why?
| | Androgens | 1 | 2021 | 187 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 327 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2022 | 362 | 0.160 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 46 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 322 | 0.160 |
Why?
| | Transcription, Genetic | 9 | 2012 | 1455 | 0.160 |
Why?
| | Neoplasm Metastasis | 3 | 2025 | 657 | 0.160 |
Why?
| | STAT5 Transcription Factor | 3 | 2014 | 57 | 0.160 |
Why?
| | RNA, Messenger | 7 | 2011 | 2831 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 389 | 0.150 |
Why?
| | Pregnancy | 3 | 2022 | 6729 | 0.150 |
Why?
| | Prolactin | 1 | 1998 | 97 | 0.150 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 622 | 0.150 |
Why?
| | Gene Amplification | 1 | 2018 | 104 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 688 | 0.150 |
Why?
| | Immunoblotting | 3 | 2010 | 306 | 0.140 |
Why?
| | Endometrial Hyperplasia | 2 | 2008 | 8 | 0.140 |
Why?
| | Antigens, CD | 1 | 2020 | 521 | 0.140 |
Why?
| | Binding Sites | 5 | 2016 | 1301 | 0.140 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 44 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2008 | 497 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 91 | 0.130 |
Why?
| | Histone Acetyltransferases | 3 | 2006 | 60 | 0.130 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 44 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 268 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 442 | 0.130 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.130 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 257 | 0.130 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.130 |
Why?
| | Cyclohexanes | 1 | 2016 | 21 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 209 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 327 | 0.130 |
Why?
| | Enzyme Inhibitors | 3 | 2024 | 839 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 217 | 0.120 |
Why?
| | Trans-Activators | 4 | 2006 | 398 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2014 | 103 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 749 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 221 | 0.120 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 194 | 0.120 |
Why?
| | Genes | 1 | 2015 | 230 | 0.120 |
Why?
| | Genetic Association Studies | 1 | 2017 | 375 | 0.120 |
Why?
| | Phosphoproteins | 2 | 2008 | 337 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 142 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 809 | 0.110 |
Why?
| | Exome | 1 | 2015 | 230 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 362 | 0.110 |
Why?
| | Tosyl Compounds | 1 | 2014 | 15 | 0.110 |
Why?
| | Genes, Reporter | 2 | 2012 | 268 | 0.110 |
Why?
| | Ligands | 6 | 2023 | 661 | 0.110 |
Why?
| | Protein Transport | 1 | 2015 | 443 | 0.110 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 162 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2016 | 729 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 96 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 316 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2412 | 0.100 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1993 | 49 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 98 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2016 | 4192 | 0.100 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 9 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4282 | 0.100 |
Why?
| | Cell Adhesion | 2 | 2012 | 466 | 0.100 |
Why?
| | Ketones | 1 | 1993 | 48 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1044 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2012 | 41 | 0.100 |
Why?
| | Middle Aged | 7 | 2024 | 33239 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2015 | 366 | 0.100 |
Why?
| | Aromatase Inhibitors | 2 | 2014 | 53 | 0.100 |
Why?
| | Metalloendopeptidases | 1 | 1992 | 62 | 0.100 |
Why?
| | Family | 1 | 2017 | 665 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 1992 | 72 | 0.100 |
Why?
| | Transduction, Genetic | 1 | 2012 | 126 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2014 | 686 | 0.090 |
Why?
| | Nuclear Proteins | 5 | 2000 | 712 | 0.090 |
Why?
| | Gene Silencing | 2 | 2014 | 195 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 149 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2023 | 769 | 0.090 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 6 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 5750 | 0.090 |
Why?
| | Receptors, Leptin | 1 | 2011 | 23 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 309 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 140 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 57 | 0.090 |
Why?
| | GTPase-Activating Proteins | 1 | 2011 | 82 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2022 | 0.090 |
Why?
| | Protein Biosynthesis | 2 | 2012 | 430 | 0.090 |
Why?
| | Fibronectins | 1 | 2011 | 133 | 0.080 |
Why?
| | Microfilament Proteins | 1 | 2011 | 131 | 0.080 |
Why?
| | Cell Transdifferentiation | 1 | 2010 | 31 | 0.080 |
Why?
| | HeLa Cells | 5 | 2006 | 633 | 0.080 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 39 | 0.080 |
Why?
| | Cyclins | 3 | 1999 | 91 | 0.080 |
Why?
| | DNA, Complementary | 4 | 2008 | 271 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 346 | 0.080 |
Why?
| | Breast | 2 | 2022 | 149 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 975 | 0.080 |
Why?
| | Protein Isoforms | 4 | 2006 | 403 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4063 | 0.080 |
Why?
| | Inflammation | 1 | 2020 | 2835 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 4013 | 0.080 |
Why?
| | Cell Line, Transformed | 1 | 2009 | 145 | 0.080 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 219 | 0.070 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1019 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3265 | 0.070 |
Why?
| | Aged | 5 | 2024 | 23808 | 0.070 |
Why?
| | Drug Interactions | 1 | 2009 | 407 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 77 | 0.070 |
Why?
| | Hysterectomy | 1 | 2008 | 128 | 0.070 |
Why?
| | Glycoproteins | 2 | 2024 | 342 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2024 | 778 | 0.070 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 65 | 0.060 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2894 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 592 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1964 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 26 | 0.060 |
Why?
| | Canada | 2 | 2017 | 421 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2006 | 169 | 0.060 |
Why?
| | Thromboplastin | 1 | 2004 | 74 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1283 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1373 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 121 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2024 | 58 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2982 | 0.050 |
Why?
| | Protein Binding | 4 | 2010 | 2216 | 0.050 |
Why?
| | Ovariectomy | 2 | 2017 | 152 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 305 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.050 |
Why?
| | Postmenopause | 3 | 2017 | 365 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2025 | 232 | 0.050 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 2138 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 31 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 423 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 58 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2005 | 613 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 217 | 0.050 |
Why?
| | Larva | 2 | 1993 | 224 | 0.050 |
Why?
| | Biology | 1 | 2022 | 88 | 0.050 |
Why?
| | Promegestone | 4 | 2005 | 33 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 678 | 0.050 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 182 | 0.050 |
Why?
| | Adult | 4 | 2016 | 37643 | 0.050 |
Why?
| | Mifepristone | 2 | 2000 | 64 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 993 | 0.040 |
Why?
| | Drug Resistance | 2 | 2000 | 169 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 543 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 558 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 283 | 0.040 |
Why?
| | Zinc | 1 | 2024 | 297 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 10748 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2020 | 72 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 18 | 0.040 |
Why?
| | Exons | 2 | 1999 | 351 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 98 | 0.040 |
Why?
| | Postpartum Period | 1 | 2022 | 338 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 13129 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 790 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 938 | 0.040 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2008 | 7593 | 0.040 |
Why?
| | Immunological Synapses | 1 | 2018 | 16 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2018 | 26 | 0.040 |
Why?
| | DNA Helicases | 1 | 2000 | 145 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 73 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 139 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 185 | 0.040 |
Why?
| | Oxygenases | 1 | 1997 | 12 | 0.040 |
Why?
| | Drug Synergism | 1 | 1998 | 383 | 0.040 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 44 | 0.030 |
Why?
| | Male | 3 | 2021 | 67330 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 362 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 416 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1231 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1998 | 313 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 49 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 206 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2005 | 1316 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 93 | 0.030 |
Why?
| | Carcinogens | 1 | 1997 | 124 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 283 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 167 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 445 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2010 | 342 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1059 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 404 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1544 | 0.030 |
Why?
| | Siblings | 1 | 2017 | 227 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 514 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 433 | 0.030 |
Why?
| | Histones | 2 | 2014 | 636 | 0.030 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 16 | 0.030 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 25 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1269 | 0.030 |
Why?
| | Base Sequence | 3 | 2008 | 2179 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 50 | 0.030 |
Why?
| | Nuclear Receptor Coactivator 1 | 2 | 2006 | 11 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 453 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 738 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 401 | 0.030 |
Why?
| | Dipeptides | 1 | 1993 | 50 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 514 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2017 | 630 | 0.030 |
Why?
| | Chromatography | 1 | 1992 | 24 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1993 | 432 | 0.020 |
Why?
| | Elastin | 1 | 1992 | 78 | 0.020 |
Why?
| | Hydrolysis | 1 | 1992 | 176 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1992 | 107 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 535 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1914 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5106 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 200 | 0.020 |
Why?
| | Oligopeptides | 1 | 1992 | 271 | 0.020 |
Why?
| | Cell Size | 1 | 2010 | 91 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2010 | 32 | 0.020 |
Why?
| | COS Cells | 2 | 2003 | 188 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2010 | 20 | 0.020 |
Why?
| | Collagen | 1 | 1992 | 446 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 144 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 85 | 0.020 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 15 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 640 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5639 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1758 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3189 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 82 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 1992 | 528 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2052 | 0.020 |
Why?
| | Cell Division | 2 | 2000 | 796 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 164 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.020 |
Why?
| | United States | 1 | 2025 | 14691 | 0.020 |
Why?
| | Trypan Blue | 1 | 2006 | 6 | 0.020 |
Why?
| | Comet Assay | 1 | 2006 | 16 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 59 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2006 | 71 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 80 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2006 | 148 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 101 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 2 | 2000 | 664 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4145 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 225 | 0.020 |
Why?
| | Androstenes | 1 | 2005 | 18 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2006 | 155 | 0.020 |
Why?
| | Caspase 3 | 1 | 2006 | 246 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2005 | 36 | 0.020 |
Why?
| | Levonorgestrel | 1 | 2005 | 38 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2006 | 160 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 374 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 148 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 231 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 110 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 316 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 487 | 0.010 |
Why?
| | DNA Damage | 1 | 2006 | 420 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 860 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 621 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 324 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 385 | 0.010 |
Why?
| | Progesterone Congeners | 1 | 2002 | 16 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 179 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 10997 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 215 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 198 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1116 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 360 | 0.010 |
Why?
| | Ku Autoantigen | 1 | 2000 | 11 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 17 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2000 | 105 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1350 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 81 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1430 | 0.010 |
Why?
| | Methionine | 1 | 2000 | 160 | 0.010 |
Why?
| | Growth Substances | 1 | 1999 | 147 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2017 | 15510 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2003 | 705 | 0.010 |
Why?
| | Estrogen Receptor beta | 1 | 1999 | 40 | 0.010 |
Why?
| | Cricetinae | 1 | 1999 | 289 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1998 | 39 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 55 | 0.010 |
Why?
| | RNA | 1 | 2005 | 921 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 131 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 162 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 24 | 0.010 |
Why?
| | Estrogen Antagonists | 1 | 1998 | 45 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 152 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 523 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 185 | 0.010 |
Why?
| | Isomerism | 1 | 1997 | 56 | 0.010 |
Why?
| | Leucine Zippers | 1 | 1997 | 17 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 283 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 389 | 0.010 |
Why?
| | Yeasts | 1 | 1997 | 53 | 0.010 |
Why?
| | Autoantigens | 1 | 2000 | 428 | 0.010 |
Why?
| | Child | 1 | 2015 | 21819 | 0.010 |
Why?
| | Blotting, Western | 1 | 1998 | 1225 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1059 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6809 | 0.010 |
Why?
| | Cell Line | 1 | 1998 | 2838 | 0.010 |
Why?
| | Models, Biological | 1 | 1998 | 1773 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2084 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|